NYSE:USNA - USANA Health Sciences Stock Price, News & Analysis

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences declared that its board has authorized a stock buyback program on Tuesday, October 23rd 2018, which allows the company to repurchase $150,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 5.9% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's management believes its stock is undervalued.

USANA Health Sciences, Inc. (NYSE:USNA) issued its quarterly earnings results on Tuesday, July, 23rd. The company reported $0.91 EPS for the quarter, missing the consensus estimate of $0.93 by $0.02. The firm earned $256 million during the quarter, compared to analyst estimates of $254.66 million. USANA Health Sciences had a net margin of 9.68% and a return on equity of 27.22%. The company's revenue for the quarter was down 15.1% on a year-over-year basis. During the same quarter last year, the company posted $1.36 earnings per share. View USANA Health Sciences' Earnings History.

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for USANA Health Sciences.

USANA Health Sciences issued an update on its FY19 earnings guidance on Tuesday, July, 23rd. The company provided EPS guidance of $3.70-4.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.89. The company issued revenue guidance of $1.02-1.06 billion, compared to the consensus revenue estimate of $1.06 billion.

3 equities research analysts have issued 1 year price objectives for USANA Health Sciences' shares. Their predictions range from $70.00 to $75.00. On average, they anticipate USANA Health Sciences' share price to reach $72.50 in the next year. This suggests a possible upside of 7.6% from the stock's current price. View Analyst Price Targets for USANA Health Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for USANA Health Sciences.

News headlines about USNA stock have trended negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. USANA Health Sciences earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for USANA Health Sciences.

USANA Health Sciences saw a decline in short interest in July. As of July 31st, there was short interest totalling 1,360,900 shares, a decline of 28.4% from the June 30th total of 1,899,600 shares. Based on an average daily trading volume, of 380,000 shares, the days-to-cover ratio is presently 3.6 days. Currently, 10.1% of the company's stock are short sold. View USANA Health Sciences' Current Options Chain.

Some companies that are related to USANA Health Sciences include Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), Cronos Group (CRON), Tilray (TLRY), Canopy Rivers (RIV), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), True Drinks (TRUU), Natural Alternatives International (NAII), Mediwound (MDWD), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), GLG Life Tech (GLGLF) and Tauriga Sciences (TAUG).

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include Tableau Software (DATA), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Allergan (AGN), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR) and Vertex Pharmaceuticals (VRTX).

USANA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.35%), Renaissance Technologies LLC (8.03%), Vanguard Group Inc. (6.45%), Acadian Asset Management LLC (3.49%), Morgan Stanley (1.34%) and D. E. Shaw & Co. Inc. (1.22%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Robeco Institutional Asset Management B.V., Prudential Financial Inc., JPMorgan Chase & Co., AQR Capital Management LLC, Bank of America Corp DE, Wells Fargo & Company MN and Vanguard Group Inc.. Company insiders that have sold USANA Health Sciences company stock in the last year include Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

USNA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, Schroder Investment Management Group, Wasatch Advisors Inc., Clark Estates Inc. NY, Invesco Ltd., D. E. Shaw & Co. Inc. and Arizona State Retirement System. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull and Myron W Wentz. View Insider Buying and Selling for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $67.41.

USANA Health Sciences has a market capitalization of $1.50 billion and generates $1.19 billion in revenue each year. The company earns $126.22 million in net income (profit) each year or $5.16 on an earnings per share basis. USANA Health Sciences employs 1,911 workers across the globe.View Additional Information About USANA Health Sciences.

The official website for USANA Health Sciences is http://www.usana.com/.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]